Technology

Regenera owns proprietary formulation intellectual property governing mineral ratios, blending methodologies, biologic integration, and complementary organic inputs across a portfolio of five distinct organic fertilizer formulations. Each formulation is engineered as a complete agronomic system designed to address specific soil and crop-use cases, combining Great Salt Lake–derived mineral inputs—originating from ancient kelp- and crustacean-rich seabed deposits—soil-biome remediation components, and biologics that support microbial activity, nutrient cycling, and plant growth. In this architecture, the mineral component is not inert; it serves as a functional, synergistic ingredient that amplifies the effectiveness of biologics and organic carriers.

These formulations are not commodity blends. They represent applied domain expertise developed through iterative design, testing, and refinement, incorporating mineral density, trace-element availability, paramagnetic effects, organic carriers, and biologic compatibility into stable, certifiable products. The value of this intellectual property is derived from its direct relationship to commercial performance, regulatory defensibility, and brand differentiation rather than from abstract patent claims alone.

From a valuation perspective, Regenera’s formulation IP is best assessed using a comparative revenue attribution approach rather than a cost-based methodology. In regulated consumer agricultural products, proprietary formulations that demonstrably support premium pricing, repeat purchase behavior, and certification compliance are commonly valued as a percentage of projected revenue attributable to the formulations themselves. Within Regenera’s model, the formulations are the primary drivers that enable premium shelf pricing, margin durability, and multi-SKU expansion.

Applying conservative industry norms, proprietary formulation platforms in specialty agriculture and organic inputs are frequently valued at between 0.50× and 1.50× forward annual revenue attributable to products relying on that intellectual property, depending on demonstrated traction, defensibility, and scalability. As Regenera scales distribution and proves market acceptance across its five formulation variants, the cumulative value of the formulation portfolio compounds as additional SKUs, channels, and use cases are layered onto the same underlying intellectual framework.

Importantly, this valuation framework avoids underpricing the creator’s expertise embedded in the formulations. The intellectual capital represented by these formulations is inseparable from the company’s ability to convert low-cost mineral and biologic inputs into premium finished goods. As such, formulation IP is treated as a core enterprise asset that directly supports revenue multiples at exit, rather than as a standalone licensing asset divorced from the operating business.

All formulations are held and controlled at the holding-company level and are inaccessible to mineral suppliers, copackers, or third parties, preserving exclusivity, transaction cleanliness, and strategic leverage in acquisition, recapitalization, or public-market integration scenarios.